Telegram分享群组www.tel8.vip)是一个Telegram群组分享平台。Telegram分享群组包括Telegram分享群组、telegram群组索引、Telegram群组导航、新加坡telegram群组、telegram中文群组、telegram群组(其他)、Telegram 美国 群组、telegram群组爬虫、电报群 科学上网、小飞机 怎么 加 群、tg群等内容。Telegram分享群组为广大电报用户提供各种电报群组/电报频道/电报机器人导航服务。

,“The gradual rise in consumer healthcare sales mix in the medium term will likely dilute the overall margins slightly, given the segment’s lower margin owing to its higher advertising and promotion costs,” CGS-CIMB Research said in its latest report.

KUALA LUMPUR: Pharmaniaga Bhd’s profit margins could see some pressures ahead on higher input costs.

The group noted in its recent briefing with *** ysts that higher input costs may potentially be felt from higher active pharmaceutical ingredient prices and the weaker ringgit to US dollar.

However, it said these factors have had a minimal impact so far on its margins, noting that this could change if the situation continues over the next three months or longer.

“The gradual rise in consumer healthcare sales mix in the medium term will likely dilute the overall margins slightly, given the segment’s lower margin owing to its higher advertising and promotion costs,” CGS-CIMB Research said in its latest report.

The research house has lowered its earnings before interest, taxes, depreciation and amortisation (Ebitda) margins forecast for Pharmaniaga slightly and expects Ebitda margin for the financial year 2022 (FY22) to contract by 3.3 percentage points to 4.6%.

“We believe our cuts sufficiently reflect the potential input cost pressures ahead,” it said.

Due to this, the research house had also cut its forecast core earnings per share for FY22-FY24 by 6% to 7.5% to factor in lower Ebitda margins and higher FY23-FY24 forecast capital expenditures for new warehouses.

CGS-CIMB Research had maintained its “add” rating on the stock but cut its target price to 73 sen, which is based on 15 times forecast price-to-earnings ratio for 2023.

Meanwhile, Pharmaniaga hopes to double or even triple its consumer healthcare revenue contribution by FY24 from a low base or less than 1% of revenue so far.

This would be supported by new product launches, which would help offset a normalisation in Vitamin C demand that was boosted by the Covid-19 surge prior to this.

“It is also exploring possible acquisitions of brands with established product ranges and customer base to expedite the consumer healthcare expansion and it has not factored this into its revenue target,” it added.

Pharmaniaga’s manufacturing plant for oral solid dosages in Bangi, Selangor, is operating at a utilisation rate of about 65%, which gives it room to ramp up output if the need arises.

“We believe the ample excess production capacity at Pharmaniaga’s existing plants will give it space for more output in the next three to five years on rising pharmaceutical demand and new product launches,” CGS-CIMB Research said.

Demand can be met with little to no incremental capital expenditures, it said.

环球UG声明:该文看法仅代表作者自己,与本平台无关。转载请注明:Telegram分享群组(www.tel8.vip)_Pressure on Pharmaniaga margins
发布评论

分享到:

Gmaing:Indonesia imposes temporary freeze on workers to Malaysia
1 条回复
  1. USDT支付平台(www.caibao.it)
    USDT支付平台(www.caibao.it)
    (2022-07-15 00:01:59) 1#

    另外,巴塞昨再有古天奴、达斯及小将伊沙苏尼(Abde Ezzalzouli)确诊新冠病毒,近日已有10人染疫,前天复操的西甲「一哥」皇家马德里,亦确认门将泰拔高图尔斯、费达历高华维迪、云尼斯奥斯祖利亚及卡马云加染疫;「银河舰队」本月较早时已有8名球员先后确诊。《阿斯报》报道,近两日结束圣诞假复操的西甲球队,合计录得86宗确诊个案,而位处巴斯克地区的皇家苏斯达、艾拉维斯及毕尔包,因应地区政府防疫政策,将入座率减至球场容量一半。可以了,很顾读者感受

发表评论

◎欢迎参与讨论,请在这里发表您的看法、交流您的观点。